ArticleMolecular biomedicine2026
Bariatric surgery may alleviate MASLD by restoring mitochondria-lipid droplet structural and functional integrity through suppression of the Mitochondrial Fission Factor-Perilipin 5 axis.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most prevalent chronic liver diseases worldwide, characterized primarily by excessive lipid droplet (LD) accumulation in hepatocytes. Bariatric surgery, particularly sleeve gastrectomy (SG), represents the most effective intervention for reversing MASLD, although the underlying mechanisms remain incompletely understood. This study aimed to investigate the mitochondrial and lipid droplets (LDs) related molecular mechanisms by which SG ameliorated MASLD. Using a high-fat diet (HFD)-induced mouse model of MASLD, combined with SG intervention, hepatocyte-specific genetic manipulation, multi-omics analysis, and mitochondrial ultrastructural examination, we observed that MASLD was associated with a marked upregulation of perilipin 5 (PLIN5) on the LD surface and mitochondrial fission factor (MFF) on the mitochondrial outer membrane. Ultrastructural and co-immunoprecipitation (Co-IP) analyses revealed that PLIN5 and MFF formed a complex that facilitated the recruitment of LDs to mitochondria and their penetration into the mitochondrial matrix. This process ultimately led to disrupted mitochondrial fatty acid β-oxidation and structural disorganization. SG significantly downregulated PLIN5 and MFF expression, reduced LD-induced mitochondrial damage, and enhanced mitochondrial resilience to high-fat stress. These changes might contribute to the restoration of mitochondria-LD structural and functional homeostasis, ultimately reversing MASLD. Our findings indicated that aberrant upregulation of MFF contributed to MASLD progression, and SG might alleviate the disease by suppressing the MFF-PLIN5 axis to normalize mitochondria-LD interactions. These results suggested that targeting the MFF-PLIN5 axis may offer a promising therapeutic strategy for non-surgical management of MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.